Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
ROCKET PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue (ASC 606) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$223.12M +13.8% |
-$258.75M -5.4% |
-$245.59M -10.7% |
-$221.86M -31.2% |
-$169.07M -21.0% |
-$139.70M -80.8% |
| Diluted EPS | -$2.01 +26.4% |
-$2.73 +6.5% |
-$2.92 +10.4% |
-$3.26 -22.1% |
-$2.67 -6.0% |
-$2.52 -59.5% |
| Total Assets | $330.45M -37.4% |
$527.70M -6.8% |
$566.34M +2.6% |
$551.81M +11.0% |
$497.02M -15.9% |
$590.82M +58.8% |
| Cash and Equivalents | $77.56M -52.6% |
$163.63M +192.7% |
$55.90M -60.2% |
$140.52M -39.6% |
$232.69M -21.7% |
$297.10M +60.3% |
| Stockholders Equity | $277.22M -40.2% |
$463.23M -6.0% |
$492.57M +0.6% |
$489.69M +7.7% |
$454.72M -9.7% |
$503.52M +63.9% |
| R&D Expense | $142.01M -17.1% |
$171.24M -8.1% |
$186.34M +12.5% |
$165.57M +32.0% |
$125.48M +19.0% |
$105.44M +82.1% |
| Operating Income | -$231.75M +15.2% |
-$273.20M -5.2% |
-$259.66M -15.7% |
-$224.34M -34.1% |
-$167.25M -24.5% |
-$134.30M -76.4% |
| Shares Outstanding | 108.32M +1.8% |
106.45M +17.9% |
90.28M +14.1% |
79.12M +22.7% |
64.51M +5.8% |
61.00M +11.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$50.33M | +24.6% | +27.0% |
| Diluted EPS | September 30, 2025 | -$0.45 | +36.6% | +27.4% |
| Total Assets | September 30, 2025 | $368.03M | -6.5% | -12.6% |
| Cash and Equivalents | September 30, 2025 | $75.95M | +15.8% | +131.4% |
| Stockholders Equity | September 30, 2025 | $313.67M | -4.9% | -11.4% |
| R&D Expense | September 30, 2025 | $34.07M | -19.5% | -20.1% |
| Operating Income | September 30, 2025 | -$52.25M | +24.7% | +26.6% |
| Shares Outstanding | September 30, 2025 | 108.21M | +18.8% | +0.3% |
- ROCKET PHARMACEUTICALS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. reported Net Income of -$223.12 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +13.8% in Net Income compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Diluted EPS of $2.01 per share (loss) for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +26.4% in Diluted EPS compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Total Assets of $330.45 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -37.4% in Total Assets compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Cash and Equivalents of $77.56 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -52.6% in Cash and Equivalents compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Stockholders Equity of $277.22 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -40.2% in Stockholders Equity compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported R&D Expense of $142.01 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -17.1% in R&D Expense compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Operating Income of -$231.75 million for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +15.2% in Operating Income compared to the prior fiscal year.
- ROCKET PHARMACEUTICALS, INC. reported Shares Outstanding of 108.32 million shares for fiscal year 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +1.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: